Nucleus Network- Business Development Consultant for California/West Coast

  Business Development Consultant for California/West Coast Business Development opportunity to represent and actively contribute to the continued growth of Australia’s largest and most successful Early Phase Clinical Research Group • Working with the World’s best Biotech/Pharma clients and CRO’s.   Nucleus Network Pty Limited (NN) is Australia’s largest Early Phase clinical trials business headquartered […]

Read More

FROM BENCH TO BEDSIDE – THE POTENTIAL OF REGENERATIVE MEDICINE

FROM BENCH TO BEDSIDE – THE POTENTIAL OF REGENERATIVE MEDICINE July 24, 2018 What if a patient could use her own cells to treat her disease? Bench-to-bedside therapeutics are possible with cell and gene therapies, and there has been steady growth in these industries over the past few years. According to the Alliance of Regenerative […]

Read More

Ask DEL BioPharma LLC: Selecting a CRO/CMO involves multiple considerations that are applicable to any component of the drug discovery/development process.  From the perspective of API manufacturing, it is critical to understand the following:

A company is looking to build a partnership with a CRO for the development of a new drug. This decision is a complex one and can play a significant role in the success for the company. What are the top 3 considerations that the company must make in their selection process to ensure that they […]

Read More

Bead-beating tissue homogenisation technology – a powerful and high throughput sample prep tool for quantitation of analyte in bone, skin & lymph node

Bead-beating tissue homogenisation technology – a powerful and high throughput sample prep tool for quantitation of analyte in bone, skin & lymph node Bhavesh Patel, Director – Head DMPK-Bioanalysis, Eurofins Advinus Limited, [email protected] Estimation of drug concentrations in tough tissues such as skin, lymph nodes, ocular tissues and bones is critical for many preclinical pharmacokinetic studies. For […]

Read More

Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.

Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc. $133 Million Deal Adds European Early Development Center of Excellence to Global Network   SOMERSET, N.J., July 3, 2018 – Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has […]

Read More

Catalent Biologics Adopts Berkeley Lights’ Beacon® Optofluidic Platform to Accelerate Cell Line Development

Catalent Biologics Adopts Berkeley Lights’ Beacon® Optofluidic Platform to Accelerate Cell Line Development   SOMERSET, N.J. – July 10, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Berkeley Lights, Inc. (BLI), a leader in digital cell biology, today announced […]

Read More